Psych MEQs / SAQs · Psychotherapy — behavioural therapies
Exposure and response prevention for residual OCD on an SRI (MEQ)
FRANZCP/MRCPsych-style MEQ on ERP definition, technique, landmark evidence, fidelity, and SRI combination for residual OCD.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Definition and cycle. ERP/EX/RP is structured behavioural treatment in which the patient confronts obsession-evoking cues while systematically refraining from compulsions and other safety behaviours.[13] Obsessions/triggers raise distress; rituals (washing, checking, reassurance) reduce distress short-term; that negative reinforcement maintains OCD. ERP breaks the relief loop so expectancy violation and inhibitory safety learning can occur.[12][13]
(ii) Assessment and hierarchy. Confirm OCD dimensions, time occupied, covert rituals, depression/suicide risk, insight, and goals. Measure severity with Y-BOCS.[14] Inventory partner reassurance and any family cleaning/checking (accommodation). Build a collaborative hierarchy from moderate public-contact and bathroom-related tasks up to higher items (e.g. toilet seat contact) with explicit response-prevention rules (delayed/no washing; no reassurance questions; limited checking). Include imaginal items if harm fears co-travel with checking. Plan therapist-assisted then self-directed practices and partner coaching to stop accommodation.[13]
(iii) Evidence for offering EX/RP now. Foa 2005: EX/RP superior to clomipramine alone; combination not clearly better than EX/RP alone at 12 weeks in that design — supports behavioural treatment as a potent standalone and combined modality.[1] For SRI residual symptoms, Simpson 2008 showed EX/RP superior to stress management augmentation; Simpson 2013 showed EX/RP superior to risperidone and placebo augmentation — aligning with his preference to add EX/RP rather than antipsychotic first when acceptable and available.[2][3] Prior "supportive CBT" was not adequate-dose ERP, so he has not yet had an evidence-based behavioural trial.
(iv) Fidelity failures. Examples: no between-session exposures; allowing washing/reassurance after contact; therapist providing repeated safety reassurance; hierarchy never leaving mild items; sessions without agenda/homework review; family undoing practice at home.[13][15]
(v) Integration and step-up. Continue sertraline 200 mg oral daily if tolerated (monitor activation, sexual side effects, hyponatraemia risk, interactions) while delivering twice-weekly or high-homework weekly EX/RP; do not stop SRI solely to "start therapy."[2][3] Step up if non-response after adequate ERP dose/fidelity: intensify schedule/residential ERP, review SRI optimisation or clomipramine pathway, treat depression/risk, specialist OCRD service — not premature polypharmacy without behavioural trial.[13]
Common errors
Calling supportive talk ERP; recommending risperidone before EX/RP without rationale; omitting response prevention; ignoring family accommodation; claiming combination always beats EX/RP alone after Foa 2005; stopping sertraline reflexively; no Y-BOCS monitoring plan.[1][3][13][14]
References
- [1]Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder Am J Psychiatry, 2005.PMID 15625214
- [2]Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder Am J Psychiatry, 2008.PMID 18316422
- [3]Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial JAMA Psychiatry, 2013.PMID 24026523
- [12]Craske MG, Treanor M, Conway CC, et al. Maximizing exposure therapy: an inhibitory learning approach Behav Res Ther, 2014.PMID 24864005
- [13]Hezel DM, Simpson HB Exposure and response prevention for obsessive-compulsive disorder: A review and new directions Indian J Psychiatry, 2019.PMID 30745681
- [14]Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability Arch Gen Psychiatry, 1989.PMID 2684084
- [15]Wheaton MG, Galfalvy H, Steinman SA, et al. Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes adherent? Behav Res Ther, 2016.PMID 27497840